Astellas stops developing autologous cell therapy for lymphomanews2025-01-08T18:14:37+00:00January 8th, 2025|Endpoints News|
Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia with Orna Therapeuticsnews2025-01-07T12:00:02+00:00January 7th, 2025|Endpoints News|
Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesnews2024-12-31T16:09:12+00:00December 31st, 2024|Endpoints News|
WuXi AppTec sells cell and gene therapy business to investornews2024-12-26T16:25:08+00:00December 26th, 2024|Endpoints News|
Mesoblast wins long-awaited approval for cell therapynews2024-12-19T20:17:15+00:00December 19th, 2024|Endpoints News|
Sangamo strikes brain-targeting AAV partnership with Astellasnews2024-12-19T07:30:53+00:00December 19th, 2024|Endpoints News|
Ring Therapeutics cuts workforce in latest round of layoffs as CEO departsnews2024-12-18T14:58:47+00:00December 18th, 2024|Endpoints News|
Shinobi adds Borges as science chief, Katz as top medical officernews2024-12-17T11:00:56+00:00December 17th, 2024|Endpoints News|
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio reviewnews2024-12-16T11:45:07+00:00December 16th, 2024|Endpoints News|
Roche terminates a Phase 3 Spark gene therapy in hemophilia Anews2024-12-16T11:20:45+00:00December 16th, 2024|Endpoints News|
